title: Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.
abstract: Cholinesterase inhibitors (ChEIs) are effective symptomatic treatments in dementia with Lewy bodies (DLB), although effects on pathologic mechanisms are unknown. In the first human autopsy study examining the impact of ChEI treatment on brain pathology, we compared treated patients with DLB with matched untreated patients for cortical beta-amyloid (Abeta) and tau pathologies. Treated patients with DLB had significantly less parenchymal Abeta deposition, which is relevant to disease management and treatment of dementia patients using ChEI.
authors.affiliation: Wolfson Centre for Age Related Diseases, Kings College London, London, UK.
authors.forename: C G
authors.initials: CG
authors.lastname: Ballard
authors.forename: K A
authors.initials: KA
authors.lastname: Chalmers
authors.forename: C
authors.initials: C
authors.lastname: Todd
authors.forename: I G
authors.initials: IG
authors.lastname: McKeith
authors.forename: J T
authors.initials: JT
authors.lastname: O'Brien
authors.forename: G
authors.initials: G
authors.lastname: Wilcock
authors.forename: S
authors.initials: S
authors.lastname: Love
authors.forename: E K
authors.initials: EK
authors.lastname: Perry
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016229:Amyloid beta-Peptides / Q000032:analysis*; D001344:Autopsy; D002540:Cerebral Cortex / Q000737:chemistry* / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D000077265:Donepezil; D004341:Drug Evaluation; D005260:Female; D005702:Galantamine / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D020961:Lewy Body Disease / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D048448:Phenylcarbamates / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011446:Prospective Studies; D000068836:Rivastigmine; D013619:Tacrine / Q000627:therapeutic use; D024801:Tauopathies / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016875:tau Proteins / Q000032:analysis
chemical_list: D016229:Amyloid beta-Peptides; D002800:Cholinesterase Inhibitors; D007189:Indans; C054369:MAPT protein, human; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D010880:Piperidines; D016875:tau Proteins; D005702:Galantamine; D013619:Tacrine; D000077265:Donepezil; D000068836:Rivastigmine